Solid IO

Executive Summary

Solid IO is a Finnish biotechnology company developing a patient-specific organ-on-chip platform that replicates the tumor microenvironment to provide real-time insights into how individual cancers respond to immuno-oncology treatments. Founded in 2018 and based in Helsinki, the company aims to eliminate guesswork in cancer care by delivering actionable, biology-driven data to clinicians and researchers. Its technology has the potential to transform precision oncology by enabling personalized treatment decisions and accelerating drug development. By mimicking the complex tumor-immune interactions ex vivo, Solid IO's platform offers a more physiologically relevant alternative to traditional in vitro models and animal testing. The company's mission addresses a critical unmet need in oncology: over 90% of experimental therapies fail in clinical trials, often due to poor predictive power of preclinical models. Solid IO's approach could improve success rates and reduce costs for pharma partners while providing oncologists with a tool to optimize therapy selection for individual patients. As the precision oncology market grows rapidly, Solid IO is well-positioned to become a key enabling technology for both clinical decision-making and drug discovery. The company has likely validated its platform in academic collaborations and is now pursuing industrial partnerships and regulatory clearances.

Upcoming Catalysts (preview)

• 2026First clinical validation study results in solid tumors70% success
• Q3 2026Partnership with a top-tier pharmaceutical company for drug testing60% success
• 2026Series A financing round to scale operations80% success